ALVO · Alvotech
$3.06
+0.65% last session
End-of-day data · updated 2026-07-28
Market cap
$1B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
13.1
Dividend yield
—
Beta
0.19
Avg volume
1M
Employees
1K
2D change
0.65%
5D change
-3.14%
10D change
-10.98%
30D change
-16.30%
60D change
-8.33%
MTD change
-13.97%
YTD change
-39.96%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ALVO
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-03-24
Latest call per bank · past 12 months
UBS
Buy$6.00
+96.1% vs priceBarclays
Underweight$4.00
+30.7% vs priceDeutsche Bank
Hold$8.00
+161.4% vs priceMorgan Stanley
Overweight$14.00
+357.5% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-03-24 | UBS | Maintains | Buy | $10.00 → $6.00 |
| 2026-03-24 | Barclays | Maintains | Underweight | $5.00 → $4.00 |
| 2025-12-09 | Barclays | Initiates | Underweight | $0.00 → $5.00 |
| 2025-11-18 | UBS | Maintains | Buy | $13.00 → $10.00 |
| 2025-11-04 | Deutsche Bank | Downgrade | Buy → Hold | $14.00 → $8.00 |
| 2025-10-14 | Morgan Stanley | Upgrade | Equal-Weight → Overweight | $0.00 → $14.00 |
| 2025-09-23 | Deutsche Bank | Upgrade | Hold → Buy | $0.00 → $14.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 38 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 11.9% below the 50-day MA ($3.52).
- Price vs 200-day MA: Trading 31.6% below the 200-day MA ($4.53).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.03) — short-term momentum is fading.
- 52-week range: Price is within 10% of the 52-week low ($3.00).
ALVO Price Chart
Loading chart for ALVO…
Fundamentals
About Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$56B 11.9% YTD
HLN
Haleon plc
$44B -0.4% YTD
TEVA
Teva Pharmaceutical Industries
$36B -0.4% YTD
ZTS
Zoetis Inc.
$32B -37.9% YTD
UTHR
United Therapeutics Corporation
$26B 8.3% YTD
VTRS
Viatris Inc.
$21B 43.9% YTD
NBIX
Neurocrine Biosciences, Inc.
$18B 24.4% YTD
ELAN
Elanco Animal Health Incorporat
$13B 12.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.